May
6,
2022
Novel Therapeutic Approaches to Target Movement Disorders: Discovery to Clinic
This lecture will discuss the basic pharmacology of Parkinson’s Disease and Dystonia, target identification and validation with novel GPCR ligands. Specifically, I will discuss the development of mGlu4 PAMs , as a pharmacological mimetic of deep bran stimulation, and the optimization of a clinical candidate that is now in Phase I MAD studies. I will then move into dystonia and our identification of the M4 mAChR subtype as the key mAChR responsible for the anti-dystonic efficacy of pan-AChR antagonists. From there, I will discuss the discovery of a weak, moderately selective M4 antagonist hit, and the subsequent optimization (and discovery caveats) that led to the discovery of a clinical candidate, currently in IND-enabling studies. For both, key med chem and DMPK lessons learned will be emphasized.
Craig W. Lindsley, PhD, is the Director of the WCNDD, a clinical stage biotech. Craig holds over 115 issued US patents and has published over 565 manuscripts. Without an industry partner, Craig oversaw IND-enabling studies of a novel M1 PAM that was awarded an open IND, and the Phase I trial was completed at Vanderbilt. Craig is the founding EIC of ACS Chemical Neuroscience, interim EIC of ACS Pharmacology & Translational Science and current EIC of Journal of Medicinal Chemistry. He was recently inducted into the ACS MEDI Hall of Fame.
Hosted by Cody Wenthur
